Sierra Oncology (Sierra Oncology) EBIT per Share : $-6.76 (TTM As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology EBIT per Share?

Sierra Oncology's EBIT per Share for the three months ended in Mar. 2022 was $-1.33. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $-6.76.

During the past 3 years, the average EBIT per Share Growth Rate was 38.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 37.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sierra Oncology's EBIT per Share or its related term are showing as below:

SRRA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -101.9 Med: 30.4 Max: 43.4
Current: 38.9

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Sierra Oncology was 43.40% per year. The lowest was -101.90% per year. And the median was 30.40% per year.

SRRA's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.4 vs SRRA: 38.90

Sierra Oncology's EBIT for the three months ended in Mar. 2022 was $-27.88 Mil.

Sierra Oncology EBIT per Share Historical Data

The historical data trend for Sierra Oncology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology EBIT per Share Chart

Sierra Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-34.18

-31.34

-23.00

-6.18

-7.14

Sierra Oncology Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EBIT per Share	Get a 7-Day Free Trial															-1.70	-1.67	-2.09	-1.67	-1.33

Sierra Oncology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sierra Oncology's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-94.585	/	13.253
=	-7.14

Sierra Oncology's EBIT per Share for the quarter that ended in Mar. 2022 is calculated as

	EBIT per Share		(Q: Mar. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-27.883	/	20.966
=	-1.33

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.76

Sierra Oncology (NAS:SRRA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sierra Oncology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sierra Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sierra Oncology (Sierra Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1820 Gateway Drive, Suite 110, San Mateo, USA, 94404

Website

https://www.sierraoncology.com

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.

Executives

Vivo Opportunity Fund Holdings, L.p.	director, 10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner	officer: Chief Reg & Tech Ops Officer	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson	officer: General Counsel	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson	director, 10 percent owner	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal	director, 10 percent owner	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair	director	C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459